Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-11-23 Capital/Financing Update
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that Verona Pharma plc has entered into a debt financing facility of up to $30 million with Silicon Valley Bank. This action directly relates to the company securing new funding and altering its capital structure to support pre-commercialization activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but a specific announcement about raising capital.
2020-11-23 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 7692F'. It discusses a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIRS, DIV, or CAP), the most appropriate fallback category is Regulatory Filings (RNS).
2020-11-18 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' multiple times. The content is a brief, time-sensitive announcement regarding a 'Price Monitoring Extension' for a security, which is a typical function of a regulatory news service feed. Given the nature of the announcement (a short, specific market operational update) and the explicit reference to RNS, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that doesn't fit the more specific categories like ER, DIV, or DIRS.
2020-11-18 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number : 7397F' and contains information about a 'Second Price Monitoring Extension' related to trading on the London Stock Exchange. The text concludes by stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This clearly identifies the document as a general regulatory announcement distributed via the RNS system, which aligns with the definition for Regulatory Filings (RNS). It is not a specific financial report, management change, or earnings release.
2020-11-18 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, short regulatory announcement regarding trading mechanics, not a comprehensive financial report or a standard corporate action like a dividend or earnings release. Since it is a general regulatory announcement provided via the RNS system that doesn't fit into the more specific categories (like DIV, ER, 10-K, etc.), the most appropriate classification is the general regulatory filing fallback category.
2020-11-18 English
SP Angel Research Note
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3015 characters) distributed via RNS (London Stock Exchange news service). The core content states that the company is 'pleased to announce that its joint broker SP Angel Corporate Finance LLP has issued an initiation research report on the Company' and directs the reader to the company website to view the note. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement that points to the publication of another document (a research report in this case) should be classified as a Report Publication Announcement (RPA). While it is a regulatory filing (RNS), RPA is more specific for announcements about the release of other reports.
2020-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.